TK1 and prostate adenocarcinoma: Moreover, higher expression of TK1 was associated with poor prognosis in several cancers, including adrenocortical carcinoma, endocervical adenocarcinoma, kidney cancer, cervical squamous cell carcinoma, lymphoid neoplasm diffuse large B-cell lymphoma, acute myeloid leukemia, hepatocellular liver carcinoma, lung adenocarcinoma, mesothelioma, prostate adenocarcinoma, and stomach adenocarcinoma (Figure S5).